Kite Pharma CEO Belldegrun on Cancer Drugs, Prices

The transcript discusses Kite Pharma's progress in developing CAR T immunotherapy, including their FDA submission process and anticipated approval timeline. It covers the company's manufacturing capabilities, market strategy, and the importance of innovation over being first to market. Pricing and patient accessibility are addressed, along with the future of immunotherapy and potential political impacts on drug regulation and funding.

How does Kite Pharma's manufacturing operation support their patient treatment goals?

What is the future outlook for immunotherapy as described in the text?

What are the potential implications of President Trump's appointees on the drug regulation environment?